Its combination with paclitaxel in patients with PTEN-deficient or PIK3CB-mutated advanced gastric cancer showed tolerability but again with limited efficacy of 18.8% partial response and DOR of only 1.8 months [141]. The gene discussed is PTEN; the disease is gastric cancer.